Result: Primary and/or secondary DR variants were found in 7.3% (15/206) of patients, and included rtL80I/V, rtI169T, rtV173L, rtL180M,
Discussion: Furthermore, some variants were related to DR to entecavir and tenofovir disoproxil fumarate, such as rtI169T, rtl180M, rtM204I/V, rtH126Y and rtD134E, which have been previously reported, and were also found in the present study.
COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B.
Abstract: Multiple-point mt were found only in 8 cases (5.6%): 6 children carried double mt (rtV207M + rtL229V; rtV207M + rtI233V; rtV207I + rtV207M x 2 cases; rtV207M + rtS213T; rtN238A + rtS256G) relating to LMV or/and ADF resistance and 3 children carried triple mt (
Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients.
Abstract: Artificial elimination of rtA181S from the rtA181S + T184I + M204I mutant restored viral susceptibility to ADV but decreased viral replication capacity.
Abstract: Compared with wild-type, the rtA181S + T184I + M204I mutant had 53.7% lower replication capacity and >1000-, 3.9-, and 383.3-fold greater LAM, ADV, and ETV resistance, respectively, but remained sensitive to tenofovir.
Abstract: Longitudinal analysis of the clinical course of resistant mutant evolution for four representative cases showed that rtA181S + T184I
Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
Result: Analysis of polymerase gene sequences from baseline and follow-up samples showed the presence of resistance-associated mutations in 5 of these 6 patients, including L180M, A181T, M204I, and M204V (Table 5).
Result: At baseline, patient ZA164 was HBsAg-positive with 7.67 x 103 IU/mL HBV DNA and the M204I variant.
Result: At the final visit at 6 months, HBV DNA level had dropped to 2.42 x 103 IU/mL, the M204I variant was not detectable, and the patient was still HBsAg-positive.
Result: Patient ZA131 was HBsAg-positive with undetectable HBV DNA levels at baseline, which increased to 3.39 x 102 IU/mL at 6 months with the
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Conclusion: Our structures also explain a common mechanism for 3TC/ETV resistance by severe steric clash between the M184V/I (M204V/I in HBV) side-chain and the oxathiolane/methylene of bound 3TC-TP/ETV-TP.
Introduction: Accordingly, we assumed that crystallographic studies of HIV-1 RT containing HBV-associated amino acids at the N-site should also provide important clues for understanding the mechanism of 3TC/ETV resistance caused by common M204V/I in HBV RT (M184V/I in HIV-1 RT).
Introduction: It is therefore of crucial importance to understand why the key M204V/I amino acid substitution leads to both 3TC and ETV resistance.
Introduction: Previous characterization of HBV RT mutants suggested that the PMID: 32915862
2020
PloS one
Table: M204I|m
Discussion: Resistance to lamivudine is best recognized in association with the rtM204V/I mutation, which is also associated with decreased viral replication fitness, leading to the subsequent selection of the compensatory mutants rtL180M, rtV173L, and rtL80I/V.
Discussion: The rtL80I mutant was most often found in presence of rtM204I as opposed to rtM204V, and most prevalent among genotype D strains; as has been previously reported.
Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
PMID: 31543688
2019
World journal of gastroenterology
Introduction: For instance, rtM204I is a classic mutation reducing susceptibility to mono-therapy by NAs with low genetic barriers, such as lamivudine (LAM), telbivudine (L-dT) and clevudine (CLV).
Introduction: Multivariate analyses showed that the naturally-occurring rtM204I variants were more frequently pre-existed in patients with liver fibrosis, and the pre-existence of the naturally-occurring rtM204I variants were significantly associated with incomplete viral response to nucleos(t)ide analogues.
Introduction: Tenofovir is a more suitable nucleos(t)ide analogues than entecavir for treatment-naive CHB patients carrying the naturally occurring
Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy.
PMID: 30906435
2019
Experimental and therapeutic medicine
Abstract: Furthermore, although in the non-responder group the frequency of the LAM resistance-associated mutations (rtM204V/I) decreased at 6 months compared with the baseline, it did not disappear in any of the patients after six months of treatment.
Abstract: In the present study, 16 Discussion: Similar to previous studies, the present study suggested that truncation mutations (rtA181T/sW172*, rtM204I/sW196* and rtV191I/sW182*) occurred at the highest frequency.
[HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
Abstract: Primary/secondary drug mutations (rtM204I/V, rtI169S, rtL180M, rtT184L, rtA194V, rtM204I/rtL91I, rtQ149K, rtQ215H/S, rtN238D) were detected in 38 (45.2%) of the patients.
HBV mutation literature information.
PMID: 
2020
World journal of gastroenterology
Browser Board
Co-occurred Entities
Filtrator
ViMRT